As of Apr 21
| -0.71 / -1.29%|
The 10 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 75.50, with a high estimate of 86.00 and a low estimate of 36.00. The median estimate represents a +38.81% increase from the last price of 54.39.
The current consensus among 10 polled investment analysts is to Buy stock in Clovis Oncology Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.